BRAF and colorectal cancer: Taken together, our results suggest that miR-193a-3p may not only serve as a tumor-suppressive miRNA involved in the oncogenesis of colorectal cancer, particularly BRAF-mutant tumors, but also may be a determinant that can affect the sensitivity to anti-EGFR therapy even in BRAF-wild-type colorectal cancer.